BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24977737)

  • 1. Malassezia pachydermatis fungaemia in an adult on posaconazole prophylaxis for acute myeloid leukaemia.
    Choudhury S; Marte RL
    Pathology; 2014 Aug; 46(5):466-7. PubMed ID: 24977737
    [No Abstract]   [Full Text] [Related]  

  • 2. No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.
    Bertz H; Drognitz K; Lübbert M
    Ann Hematol; 2014 Jan; 93(1):165-7. PubMed ID: 23949313
    [No Abstract]   [Full Text] [Related]  

  • 3. Posaconazole prophylaxis in hematologic cancer.
    van Nieuwkoop C; van Dissel JT
    N Engl J Med; 2007 May; 356(21):2215; author reply 2215-8. PubMed ID: 17526089
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
    Bryant AM; Slain D; Cumpston A; Craig M
    Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.
    Dellacasa CM; Busca A; Audisio E; Marmont F; Barbui AM; Falda M; De Rosa FG; Frairia C; Allione B; D'Ardia S; Aydin S; Pecoraro C; Manetta S; Vitolo U
    J Chemother; 2014 Oct; 26(5):315-20. PubMed ID: 24075616
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
    Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
    Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
    Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
    J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal Prophylaxis With Posaconazole Is Effective in Preventing Invasive Fungal Infections in Acute Myeloid Leukemia Patients During Induction and Salvage Chemotherapy.
    Wong GC; Abdul Halim NA; Tan BH
    Clin Infect Dis; 2015 Oct; 61(8):1351-2. PubMed ID: 26139846
    [No Abstract]   [Full Text] [Related]  

  • 12. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
    Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
    Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    AbuTarif MA; Krishna G; Statkevich P
    Curr Med Res Opin; 2010 Feb; 26(2):397-405. PubMed ID: 20001450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole prophylaxis in hematologic cancer.
    Weiler S; Bellmann R
    N Engl J Med; 2007 May; 356(21):2214; author reply 2215-8. PubMed ID: 17522407
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
    Gerber B; Köppel J; Paul M; Nguyen-Kim TD; Frauenfelder T; Nair G; Schanz U; Manz MG
    Swiss Med Wkly; 2014; 144():w13985. PubMed ID: 25055166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.
    Berking S; Doedens D; Horns H; Fiegl M; Ostermann H; Rieger CT
    Mycoses; 2017 Sep; 60(9):600-606. PubMed ID: 28504318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acremonium strictum fungaemia in a paediatric immunocompromised patient: diagnosis and treatment difficulties.
    Hitoto H; Pihet M; Weil B; Chabasse D; Bouchara JP; Rachieru-Sourisseau P
    Mycopathologia; 2010 Sep; 170(3):161-4. PubMed ID: 20340045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal disseminated infection due to Scedosporium prolificans in a patient with acute myeloid leukemia and posaconazole prophylaxis.
    Rivier A; Perny J; Debourgogne A; Thivillier C; Lévy B; Gérard A; Machouart M
    Leuk Lymphoma; 2011 Aug; 52(8):1607-10. PubMed ID: 21649548
    [No Abstract]   [Full Text] [Related]  

  • 20. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
    Vehreschild JJ; Krüger K; Kurzai O; Wickenhauser C; Behringer K; Töx U; Cornely OA
    Mycoses; 2006; 49 Suppl 1():42-7. PubMed ID: 16961582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.